Immune and targeted therapy for cancer: time to rethink restrictions for the treatment of the elderly and frail

ABSTRACT

Targeted and immunotherapy have revolutionized cancer treatment. They safely substitute for traditional chemotherapy in a significant and growing number of malignancies. In this article, we review the United States Food and Drug Administration (FDA) - approved targeted and immunotherapies, currently used in oncology and compare their safety and efficacy in young versus geriatric and frail sub-population. The results suggest an overall comparable, if not superior efficacy in several tumor types, with acceptable toxicities across the board compared to cytotoxic chemotherapy and a favorable analysis in the comparison to the results observed in the younger population. The very decision to place elderly patients on exclusive palliative care can no longer be supported based on age or frailty alone. The historical concept of medical oncologists leaning for palliative treatments for these patients needs to be revisited.

RESUMO

A imunoterapia direcionada revolucionou o tratamento do câncer. Eles substituem com segurança a quimioterapia tradicional em um número significativo e crescente de doenças malignas. Neste artigo, revisamos a Food and Drug Administration (FDA) - imunoterapias direcionadas aprovadas atualmente usadas em oncologia, e comparamos sua segurança e eficácia na subpopulação jovem versus geriátrica e frágil. Com resultados sugerindo uma eficácia geral comparável, se não superior, em vários tipos de tumor com toxicidades aceitáveis em toda a linha em comparação com a quimioterapia citotóxica, e uma análise favorável na comparação com os resultados observados na população mais jovem. A própria decisão de colocar pacientes idosos em cuidados paliativos exclusivos não pode mais ser sustentada apenas com base na idade ou fragilidade. O conceito histórico de médicos oncologistas que buscam tratamentos paliativos para esses pacientes precisa ser revisitado.

Keywords:

Molecular targeted therapy - Immunotherapy - Therapeutics - Frail elderly - Aged.

Descritores:

Terapia de alvo molecular - Imunoterapia - Terapêutica - Idoso frágil - Envelhecido.

• REFERENCES

• White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ.. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 2014; Mar; 46 (3 Suppl 1); S7-S15
• Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M. et al International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014; Aug; 32 (24) 2595-2603
• Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A.. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol 2018; Jun; 19 (06) e305-e16
• Darvin P, Toor SM, Nair VS, Elkord E.. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018; Dec; 50 (12) 1-11
• Helissey C, Vicier C, Champiat S.. The development of immunotherapy in older adults: new treatments, new toxicities?. J Geriatr Oncol 2016; Sep; 7 (05) 325-333
• Hanahan D, Weinberg RA.. Hallmarks of cancer: the next generation. Cell 2011; Mar; 144 (05) 646-674
• Elias R, Karantanos T, Sira E, Hartshorn KL.. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol 2017; May; 8 (03) 229-235
• Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY. et al Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020; 38 (03) 193-202
• Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF. et al First-Line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 2019; Apr; 37 (12) 992-1000
• Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ. et al Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non- smallcell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393 (10183): 1819-1830
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A. et al Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; Nov; 375 (+19); 1823-1833
• Elias R, Morales J, Rehman Y, Khurshid H.. Immune checkpoint inhibitors in older adults. Curr Oncol Rep 2016; Aug; 18 (08) 47
• Nishijima TF, Muss HB, Shachar SS, Moschos SJ.. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta- analysis. Cancer Treat Rev 2016; 45: 30-37
• Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM.. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Eur J Cancer 2019; Aug; 119: 122-131
• Barlesi F, Audigier-Valette C, Felip E, Ciuleanu T, Jao K, Rijavec E. et al OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. J Thorac Oncol 2019; Oct; 14 (10) S214-S5
• Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J. et al Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020; Sep; 8 (09) 895-904
• Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T. et al First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; Nov; 18 (11) 1483-1492
• Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM. et al Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). J Thorac Oncol 2019; Sep; 14 (09) 1628-1639
• Sbrana A, Antognoli R, Pasqualetti G, Linsalata G, Okoye C, Calsolaro V. et al Effectiveness of multi-prognostic index in older patients with advanced malignancies treated with immunotherapy. J Geriatr Oncol 2020; Apr; 11 (03) 503-507
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D. et al Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; Apr; 344 (14) 1052-1056
• Garraway LA.. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; May; 31 (15) 1806-1814
• Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR. et al Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; Jun; 23 (06) 703-713
• Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD. et al Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; Feb; 378 (08) 731-739
• Suidan AM, Roisman L, Rozenblum AB, Ilbouze M, Dudnik E, Zer A. et al Lung cancer in young patients: higher rate of driver mutations and brain involvement, but better survival. J Glob Oncol 2019; May; 5: 1-8
• Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015; Jun; 161 (07) 1681-1696
• Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA. et al Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 2014; Mar; 110 (05) 1125-1132
• Brunello A, Basso U, Sacco C, Sava T, Vivo R, Camerini A. et al Safety and activity of sunitinib in elderly patients (>70 years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol 2013; Feb; 24 (02) 336-342
• Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R. et al Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; Oct; 100 (20) 1454-1463
• Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE. et al Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; Nov; 378 (9807) 1931-1939
• Merimsky O, Cheng CK, Au JS, Von Pawel J, Reck M.. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Oncol Rep 2012; Aug; 28 (02) 721-727
• Wheatley-Price P, Ding K, Seymour L, Clark GM, Sheperd FA.. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; May; 26 (14) 2350-2357
• Bedas A, Peled N, Rabinovich NM, Mishaeli M, Schochat T, Zer A. et al Efficacy and safety of ALK tyrosine kinase inhibitors in elderly patients with advanced alk-positive non-small cell lung cancer: findings from the real-life cohort. Oncol Res Treat 2019; 42 (05) 275-282
• Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM. et al Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; Sep; 17 (09) 1248-1260
• Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E. et al Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; Aug; 381 (07) 626-636
• Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A. et al Targeted therapy and elderly people: a review. Eur J Cancer 2016; Dec; 69: 199-215
• Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ. et al Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 2014; Aug; 32 (24) 2587-2594
• Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ. et al Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; Apr; 21 (07) 1383-1389
• Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. Surveillance, epidemiology, and end results (SEER) Program SEER*Stat Database: Mortality - Total U.S. (1969-2016). Bethesda: National Cancer Institute (NIH);; 2019
• Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A. et al End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer-- Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. J Clin Oncol 2013; Oct; 31 (29) 3711-3718
• Soubeyran P, Bellera C, Goyard J, Heitz D, Cure H, Rousselot H. et al Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One 2014; Dec; 9 (12) e115060
• Owusu C, Koroukian SM, Schluchter M, Bakaki P, Berger NA.. Screening older cancer patients for a comprehensive geriatric assessment: a comparison of three instruments. J Geriatr Oncol 2011; Apr; 2 (02) 121-129
• Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellman MD.. Impact of PD-1 blockade on severity of COVID19 in patients with lung cancers. Cancer Discovery 2020; May; 12; Epub ahead of print.